<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "5: Integrating ", fill: "#ace5ee"},
{source: "5: Integrating ", target: "5: businesses however involves", fill: "#ace5ee"},
{source: "5: businesses however involves", target: "5: possibility", fill: "#ace5ee"},
{source: "5: possibility", target: "5: management may", fill: "#ace5ee"},
{source: "5: management may", target: "5: distracted from", fill: "#ace5ee"},
{source: "5: distracted from", target: "5: concerns by", fill: "#ace5ee"},
{source: "5: concerns by", target: "5: Contents ", fill: "#ace5ee"},
{source: "5: Contents ", target: "5: Financial Statements ", fill: "#ace5ee"},
{source: "5: Financial Statements ", target: "5: integrate operations unforeseen difficulties", fill: "#ace5ee"},
{source: "5: integrate operations unforeseen difficulties", target: "5: integrating operations", fill: "#ace5ee"},
{source: "5: integrating operations", target: "5: systems problems assimilating", fill: "#ace5ee"},
{source: "5: systems problems assimilating", target: "5: company accounting issues", fill: "#ace5ee"},
{source: "5: company accounting issues", target: "5: connection", fill: "#ace5ee"},
{source: "5: connection", target: "5: acquisition", fill: "#ace5ee"},
{source: "5: acquisition", target: "5: company regulatory", fill: "#ace5ee"},
{source: "5: company regulatory", target: "5: compliance issues", fill: "#ace5ee"},
{source: "5: compliance issues", target: "5: company challenges", fill: "#ace5ee"},
{source: "5: company challenges", target: "5: company following", fill: "#ace5ee"},
{source: "5: company following", target: "5: potential adverse", fill: "#ace5ee"},
{source: "5: potential adverse", target: "5: term effects on", fill: "#ace5ee"},
{source: "5: term effects on", target: "5: through increased costs", fill: "#ace5ee"},
{source: "5: Integrating ", target: "9: meet such demands", fill: "#318ce7"},
{source: "9: meet such demands", target: "9: new technology", fill: "#318ce7"},
{source: "9: new technology", target: "9: capital expenditures", fill: "#318ce7"},
{source: "9: capital expenditures", target: "9: particular demands", fill: "#318ce7"},
{source: "9: meet such demands", target: "10: successfully", fill: "#0d98ba"},
{source: "10: successfully", target: "10: acquisitions", fill: "#0d98ba"},
{source: "10: acquisitions", target: "10: timely manner", fill: "#0d98ba"},
{source: "10: timely manner", target: "10: efficiently manage operations", fill: "#0d98ba"},
{source: "10: efficiently manage operations", target: "10: accommodates continued internal", fill: "#0d98ba"},
{source: "10: accommodates continued internal", target: "10: financial condition", fill: "#0d98ba"},
{source: "10: financial condition", target: "10: adversely affected", fill: "#0d98ba"},
{source: "10: successfully", target: "12: three companies representing three lines", fill: "#ace5ee"},
{source: "12: three companies representing three lines", target: "12: independent", fill: "#ace5ee"},
{source: "12: independent", target: "12: Coblation ", fill: "#ace5ee"},
{source: "12: Coblation ", target: "12: Atlantech ", fill: "#ace5ee"},
{source: "12: Atlantech ", target: "12: instruments", fill: "#ace5ee"},
{source: "12: instruments", target: "12: of Parallax ", fill: "#ace5ee"},
{source: "12: of Parallax ", target: "12: bone cement", fill: "#ace5ee"},
{source: "12: three companies representing three lines", target: "16: unsuccessful", fill: "#5a4fcf"},
{source: "16: unsuccessful", target: "16: integrating", fill: "#5a4fcf"},
{source: "16: integrating", target: "16: businesses", fill: "#5a4fcf"},
{source: "16: businesses", target: "16: disruptions", fill: "#5a4fcf"},
{source: "16: disruptions", target: "16: integration efforts then", fill: "#5a4fcf"},
{source: "16: integration efforts then", target: "16: financial condition", fill: "#5a4fcf"},
{source: "16: financial condition", target: "16: operations", fill: "#5a4fcf"},
{source: "16: operations", target: "16: future growth prospects could", fill: "#5a4fcf"},
{source: "16: future growth prospects could", target: "16: materially adversely", fill: "#5a4fcf"},
{source: "16: unsuccessful", target: "17: current products", fill: "#ffcba4"},
{source: "17: current products", target: "17: core businesses", fill: "#ffcba4"},
{source: "17: core businesses", target: "17: competitive", fill: "#ffcba4"},
{source: "17: current products", target: "19: cannot assure", fill: "#c154c1"},
{source: "19: cannot assure", target: "19: companies will", fill: "#c154c1"},
{source: "19: companies will", target: "19: technologies", fill: "#c154c1"},
{source: "19: technologies", target: "19: effective than ours", fill: "#c154c1"},
{source: "19: effective than ours", target: "19: technology", fill: "#c154c1"},
{source: "19: technology", target: "19: products obsolete", fill: "#c154c1"},
{source: "19: products obsolete", target: "19: uncompetitive", fill: "#c154c1"},
{source: "19: cannot assure", target: "START_HERE", fill: "#c154c1"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
    <tr>
      <td>Electronic Equipment and Instruments</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
    <tr>
      <td>Environmental Services</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Reduce routine activity</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Covert monitoring</td>
    </tr>
    <tr>
      <td>Comment</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Contents_insurance">Contents insurance</a></td>
      <td>Contents insurance is insurance that pays for damage to, or loss of, an individual’s personal possessions while they are located within that individual’s home. Some contents insurance policies also provide restricted cover for personal possessions temporarily taken away from the home by the policyholder.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Table_of_contents">Table of contents</a></td>
      <td>A table of contents, usually headed simply Contents and abbreviated informally as TOC, is a list, usually found on a page before the start of a written work, of its chapter or section titles or brief descriptions with their commencing page numbers.\n\n\n== History ==\nPliny the Elder credits Quintus Valerius Soranus (d.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Current_Contents">Current Contents</a></td>
      <td>Current Contents is a rapid alerting service database from Clarivate Analytics, formerly the Institute for Scientific Information and Thomson Reuters. It is published online and in several different printed subject sections.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/SM_Culture_&amp;_Contents">SM Culture &amp; Contents</a></td>
      <td>SM Culture &amp; Contents (Korean: 에스엠컬처앤콘텐츠; SM C&amp;C) is a South Korean advertising, production, travel and talent company under SM Studios, a wholly-owned subsidiary of SM Entertainment. The company operates as a talent agency, television content production company, theatrical production company and travel company.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Victory_Contents">Victory Contents</a></td>
      <td>Victory Contents (Korean: 빅토리콘텐츠; RR: bigtoli kontencheu) is a Korean drama production company based in Seoul.\n\n\n== History ==\nsource: \n\nApril 4, 2003 - Music Encyclopedia was established.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Table_of_Contents_(Enochs)">Table of Contents (Enochs)</a></td>
      <td>Table of Contents is a sculpture designed by the American artist Dale Enochs. The sculpture is made from limestone and was commissioned by Joseph F. Miller.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Contents_of_the_Book_of_Leinster">Contents of the Book of Leinster</a></td>
      <td>The following table of contents for the Book of Leinster is based on the diplomatic edition by R.I. Best and M.A. O'Brien. The contents are listed according to the folio number of the manuscript and the page and volume number of the edition.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_statement">Financial statement</a></td>
      <td>Financial statements (or financial reports) are formal records of the financial activities and position of a business, person, or other entity.\nRelevant financial information is presented in a structured manner and in a form which is easy to understand.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Balance_sheet">Balance sheet</a></td>
      <td>In financial accounting, a balance sheet (also known as statement of financial position or statement of financial condition) is a summary of the financial balances of an individual or organization, whether it be a sole proprietorship, a business partnership, a corporation, private limited company or other organization such as government or not-for-profit entity. Assets, liabilities and ownership equity are listed as of a specific date, such as the end of its financial year.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_ratio">Financial ratio</a></td>
      <td>A financial ratio or accounting ratio is a relative magnitude of two selected numerical values taken from an enterprise's financial statements. Often used in accounting, there are many standard ratios used to try to evaluate the overall financial condition of a corporation or other organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Educational_technology">Educational technology</a></td>
      <td>Educational technology (commonly abbreviated as edutech, or edtech) is the combined use of computer hardware, software, and educational theory and practice to facilitate learning. When referred to with its abbreviation, edtech, it is often referring to the industry of companies that create educational technology.In addition to practical educational experience, educational technology is based on theoretical knowledge from various disciplines such as communication, education, psychology, sociology, artificial intelligence, and computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology">Information technology</a></td>
      <td>Information technology (IT) is the use of computers to create, process, store, retrieve, and exchange all kinds of electronic data and information. IT is typically used within the context of business operations as opposed to personal or entertainment technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_condition_report">Financial condition report</a></td>
      <td>In accounting, a financial condition report (FCR) is a report on the solvency condition of an insurance company that takes into account both the current financial status, as reflected in the balance sheet, and an assessment of the ability of the company to survive future risk scenarios. Risk assessment in an FCR involves dynamic solvency testing, a type of dynamic financial analysis that simulates management response to risk scenarios, to test whether a company could remain solvent in the face of deteriorating economic conditions or major disasters.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_law">Financial law</a></td>
      <td>Financial law is the law and regulation of the insurance, derivatives, commercial banking, capital markets and investment management sectors. Understanding Financial law is crucial to appreciating the creation and formation of banking and financial regulation, as well as the legal framework for finance generally.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Trustmark_(bank)">Trustmark (bank)</a></td>
      <td>Trustmark is a commercial bank and financial services company headquartered in Jackson, Mississippi, United States, with subsidiaries Trustmark National Bank, Trustmark Investment Advisors, and Fisher Brown Bottrell Insurance. The bank's initial predecessor, The Jackson Bank, was chartered by the State of Mississippi in 1889.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_analysis">Financial analysis</a></td>
      <td>Financial analysis (also referred to as financial statement analysis or accounting analysis or Analysis of finance) refers to an assessment of the viability, stability, and profitability of a business, sub-business or project. \nIt is performed by professionals who prepare reports using ratios and other techniques, that make use of information taken from financial statements and other reports.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Form_10-K">Form 10-K</a></td>
      <td>A Form 10-K is an annual report required by the U.S. Securities and Exchange Commission (SEC), that gives a comprehensive summary of a company's financial performance. Although similarly named, the annual report on Form 10-K is distinct from the often glossy "annual report to shareholders," which a company must send to its shareholders when it holds an annual meeting to elect directors (though some companies combine the annual report and the 10-K into one document).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Federal_takeover_of_Fannie_Mae_and_Freddie_Mac">Federal takeover of Fannie Mae and Freddie Mac</a></td>
      <td>In September 2008 the Federal Housing Finance Agency (FHFA) announced that it would take over the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac). Both government-sponsored enterprises, which finance home mortgages in the United States by issuing bonds, had become illiquid as the market for those bonds collapsed in the subprime mortgage crisis.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Plantar_fasciitis">Plantar fasciitis</a></td>
      <td>Plantar fasciitis is a disorder of the plantar fascia, which is the connective tissue which supports the arch of the foot. It results in pain in the heel and bottom of the foot that is usually most severe with the first steps of the day or following a period of rest.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Laser_surgery">Laser surgery</a></td>
      <td>Laser surgery is a type of surgery that uses a laser (in contrast to using a scalpel) to cut tissue.Examples include the use of a laser scalpel in otherwise conventional surgery, and soft-tissue laser surgery, in which the laser beam vaporizes soft tissue with high water content.\nLaser surgery is commonly used on the eye.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition">Competition</a></td>
      <td>Competition is a rivalry where two or more parties strive for a common goal which cannot be shared: where one's gain is the other's loss (an example of which is a zero-sum game). Competition can arise between entities such as organisms, individuals, economic and social groups, etc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology_company">Technology company</a></td>
      <td>A technology company (or tech company) is an electronics-based technological company, including, for example, business relating to digital electronics, software, and internet-related services, such as e-commerce services.\n\n\n== Details ==\nAccording to Fortune, as of 2020, the ten largest technology companies by revenue are: Apple Inc., Samsung, Foxconn, Alphabet Inc., Microsoft, Huawei, Dell Technologies, Hitachi, IBM, and Sony.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology_management">Technology management</a></td>
      <td>Technology management is a set of management disciplines that allows organizations to manage their technological fundamentals to create customer advantage. Typical concepts used in technology management are:\n\nTechnology strategy (a logic or role of technology in organization),\nTechnology forecasting (identification of possible relevant technologies for the organization, possibly through technology scouting),\nTechnology roadmap (mapping technologies to business and market needs), and\nTechnology project portfolio (a set of projects under development) and technology portfolio (a set of technologies in use).The role of the technology management function in an organization is to understand the value of certain technology for the organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Language_technology">Language technology</a></td>
      <td>Language technology, often called human language technology (HLT), studies methods of how computer programs or electronic devices can analyze, produce, modify or respond to human texts and speech. Working with language technology often requires broad knowledge not only about linguistics but also about computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Space_technology">Space technology</a></td>
      <td>Space technology is technology for use in outer space, in travel (astronautics) or other activities beyond Earth's atmosphere, for purposes such as spaceflight, space exploration, and Earth observation. Space technology includes space vehicles such as spacecraft, satellites, space stations and orbital launch vehicles; deep-space communication; in-space propulsion; and a wide variety of other technologies including support infrastructure equipment, and procedures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology_consulting">Information technology consulting</a></td>
      <td>In management, information technology consulting (also called IT consulting, computer consultancy, business and technology services, computing consultancy, technology consulting, and IT advisory) is a field of activity which focuses on advising organizations on how best to use information technology (IT) in achieving their business objectives.\nOnce a business owner defines the needs to take a business to the next level, a decision maker will define a scope, cost and a time frame of the project.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bachelor_of_Technology">Bachelor of Technology</a></td>
      <td>A Bachelor of Technology (Latin Baccalaureus Technologiae, commonly abbreviated as B.Tech. or BTech; with honours as B.Tech.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>ARTHROCARE CORP      ITEM 1A    RISK FACTORS        We operate in a dynamic and rapidly changing industry that <font color="blue">involves numerous</font>     risks and <font color="blue">uncertainties</font></td>
    </tr>
    <tr>
      <td>The risks and <font color="blue">uncertainties</font> described below are     those that we currently believe <font color="blue">may <font color="blue">materially</font> <font color="blue">affect us</font></font></td>
    </tr>
    <tr>
      <td>Other risks and     <font color="blue">uncertainties</font> that we do not presently consider to be material or of which     we are not presently aware, may become important factors that <font color="blue">affect us</font> in     the future</td>
    </tr>
    <tr>
      <td><font color="blue">Circumstances Associated </font>with Our <font color="blue">Acquisition </font>Strategy and Internal Growth     May Adversely Affect Our Operating Results        An  important  element  of our <font color="blue">growth strategy</font> has been the pursuit of     <font color="blue"><font color="blue">acquisition</font>s</font> of other <font color="blue">businesses</font> that expand or <font color="blue">complement</font> our existing     products</td>
    </tr>
    <tr>
      <td><font color="blue">Integrating </font><font color="blue">businesses</font>, however, involves a number of special     risks, including the <font color="blue">possibility</font> that <font color="blue">management may</font> be <font color="blue">distracted from</font>     regular business <font color="blue">concerns by</font> the need to                                           19     ______________________________________________________________________    [59]Table of <font color="blue">Contents    </font>[60]Index to <font color="blue">Financial Statements       </font>integrate <font color="blue">operations</font>, unforeseen <font color="blue"><font color="blue">difficult</font>ies</font> in <font color="blue"><font color="blue">integrating</font> <font color="blue">operations</font></font> and     systems, problems assimilating and retaining our employees or the employees     of the acquired company, accounting issues that could arise in <font color="blue">connection</font>     with, or as a result of, the <font color="blue">acquisition</font> of the acquired company, <font color="blue">regulatory</font>     or <font color="blue">compliance issues</font> that could exist at an acquired company, <font color="blue">challenges</font> in     retaining our customers or the customers of the acquired <font color="blue">company following</font>     the  <font color="blue">acquisition</font> and <font color="blue">potential adverse</font> short <font color="blue">term effects on</font> operating     results <font color="blue">through increased costs</font> or otherwise</td>
    </tr>
    <tr>
      <td>In addition, we will incur     <font color="blue"><font color="blue">additional</font> debt</font> to <font color="blue">fund future payments</font> to Opus <font color="blue">stockholders</font> and ATI and, we     may incur debt to finance future <font color="blue"><font color="blue">acquisition</font>s</font> and/or may issue securities in     <font color="blue">connection</font> with future <font color="blue"><font color="blue">acquisition</font>s</font> which may dilute the holdings of our     current and future <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>In addition to the risks associated with <font color="blue">acquisition</font>-related growth, our     business has grown in size and <font color="blue"><font color="blue">complexity</font> over</font> the <font color="blue">past few years as</font> a     result of <font color="blue">internal growth</font></td>
    </tr>
    <tr>
      <td>This growth and increase in <font color="blue">complexity</font> have     placed <font color="blue">significant</font> demands on management, systems, internal controls and     financial  and  <font color="blue">physical resources</font></td>
    </tr>
    <tr>
      <td>To <font color="blue">meet such demands</font>, we intend to     continue to invest in <font color="blue">new <font color="blue">technology</font></font>, make other <font color="blue">capital <font color="blue">expenditures</font></font> and,     where appropriate, hire and/or train employees with expertise to handle     these <font color="blue">particular demands</font></td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">successfully</font> complete and     integrate  strategic  <font color="blue"><font color="blue">acquisition</font>s</font> in a <font color="blue">timely manner</font> or if we fail to     <font color="blue">efficiently manage <font color="blue">operations</font></font> in a way that <font color="blue">accommodates continued internal</font>     growth, our business, <font color="blue">financial condition</font> or operating results could be     <font color="blue"><font color="blue">adversely affect</font>ed</font></td>
    </tr>
    <tr>
      <td>In 2005, we acquired <font color="blue">substantially</font> all of the assets of ATI, a maker of     wound care products for ear, nose and throat (ENT) <font color="blue">indications</font></td>
    </tr>
    <tr>
      <td>In 2004 and     2002, we acquired <font color="blue">three companies representing three lines</font> of business     <font color="blue">in<font color="blue">dependent</font></font> of our core <font color="blue">Coblation </font>platform: <font color="blue">Atlantech </font>and its mechanical     handheld <font color="blue">instruments</font>; MDA and its line <font color="blue">of Parallax </font><font color="blue">bone cement</font> and delivery     systems; and Opus and its line of tissue suturing and anchoring products</td>
    </tr>
    <tr>
      <td><font color="blue">Integration </font>of these <font color="blue">businesses</font> has been a <font color="blue">significant</font> challenge to our     existing resources</td>
    </tr>
    <tr>
      <td>At times, these <font color="blue">integration issues</font> have <font color="blue">restricted sales</font>     of one or more <font color="blue"><font color="blue">product line</font>s as</font> a host of systems, <font color="blue">distribution</font>, logistics     and <font color="blue">product supply issues</font> have <font color="blue">materialized</font></td>
    </tr>
    <tr>
      <td>While we are <font color="blue">diligently focused</font>     <font color="blue">on successful integration</font>, the newness of these <font color="blue"><font color="blue">technologies</font> along with</font> the     dispersed nature of the <font color="blue">product <font color="blue">development</font></font> and <font color="blue">supply chain represents</font> a     risk to our business and <font color="blue">availability</font> of <font color="blue">internal resources</font></td>
    </tr>
    <tr>
      <td>If we are     <font color="blue">unsuccessful</font> in <font color="blue">integrating</font> these <font color="blue">businesses</font>, or experience <font color="blue"><font color="blue">disruption</font>s</font>     related to our integration efforts, then our <font color="blue">financial condition</font>, results of     <font color="blue">operations</font>  and  <font color="blue"><font color="blue">future growth prospects</font> could</font> be <font color="blue"><font color="blue">materially</font> adversely</font>     affected</td>
    </tr>
    <tr>
      <td>We Face Intense Competition        The markets for our <font color="blue">current products</font> in our core <font color="blue">businesses</font> are intensely     <font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>These markets include <font color="blue">arthroscopy</font>, <font color="blue">spinal surgery</font> <font color="blue">and ENT </font>    surgery</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that other <font color="blue">companies will</font> not succeed in     developing <font color="blue">technologies</font> and products that are more <font color="blue"><font color="blue">effective</font> than ours</font>, or     that would render our <font color="blue">technology</font> or <font color="blue">products obsolete</font> or un<font color="blue">competitive</font> in     these markets</td>
    </tr>
    <tr>
      <td>In <font color="blue">arthroscopy</font>, we compete <font color="blue">against companies</font>, such as Johnson &amp; Johnson,     Smith &amp;  Nephew, Inc, Conmed Corporation, Stryker Corp, and Arthrex</td>
    </tr>
    <tr>
      <td>Specifically, Johnson &amp; Johnson, Smith &amp; Nephew and Stryker are currently     <font color="blue">marketing bipolar electrosurgical systems</font> for <font color="blue">tissue ablation</font> and shrinkage     and Arthrex and Conmed are <font color="blue">currently marketing monopolar electrosurgical</font>     systems  for  tissue  ablation</td>
    </tr>
    <tr>
      <td>Arthrex,  Smith &amp; Nephew, Conmed, and     DePuy-Mitek <font color="blue">market products</font> that <font color="blue">directly <font color="blue">compete with</font> shoulder anchors</font>,     acquired as part of our Opus <font color="blue">acquisition</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">spinal surgery</font>, we compete     <font color="blue">against companies</font> that <font color="blue">market products</font> to <font color="blue">remove tissue</font> and <font color="blue">treat spinal</font>     disorders</td>
    </tr>
    <tr>
      <td>We <font color="blue">compete against</font> Stryker, <font color="blue">which markets</font> the Dekompressor     device, <font color="blue">which uses</font> a <font color="blue">mechanical auger</font> to perform <font color="blue"><font color="blue">percutaneous</font> <font color="blue">discectomy</font></font></td>
    </tr>
    <tr>
      <td>In     addition, the Oratec division of Smith &amp; Nephew, and the Radionics division     of Tyco, are currently marketing <font color="blue">percutaneous</font> thermal heating products for     <font color="blue">treating certain types</font> of disc pain</td>
    </tr>
    <tr>
      <td>Our Coblation-assisted <font color="blue">micro<font color="blue">discectomy</font></font>     (CAM) <font color="blue">procedure competes indirectly with</font> large <font color="blue">spine companies</font> and their     mechanical <font color="blue">instruments</font>, such as DePuy Acromed, Medtronic Sofamor Danek,     Centerpulse Spine Tech, Stryker Spine and Synthes</td>
    </tr>
    <tr>
      <td>Stryker, Cardinal Health,     Cook and Kyphon <font color="blue">market products</font> that <font color="blue">compete directly with</font> our <font color="blue">Parallax     </font><font color="blue">product line</font></td>
    </tr>
    <tr>
      <td>In ENT surgery, we compete <font color="blue">against companies</font> that <font color="blue">offer manual</font>     <font color="blue">instruments</font>,  such  as  Smith &amp;  Nephew,  Inc,  Stryker Corp, Conmed     Corporation,  and  Xomed Surgical Products Inc, which was acquired by     Medtronic, Inc</td>
    </tr>
    <tr>
      <td>In addition, we compete                                           20     ______________________________________________________________________    [61]Table of <font color="blue">Contents    </font>[62]Index to <font color="blue">Financial Statements       </font>with  companies that develop and <font color="blue">market lasers</font> for various ENT surgery     <font color="blue"><font color="blue">application</font>s</font>, including Lumenis</td>
    </tr>
    <tr>
      <td>(<font color="blue">purchased by</font> Gyrus Group International, Inc, a company     based in Cardiff, Wales), <font color="blue">also sell <font color="blue">medical devices</font></font> for the treatment of     various ENT disorders, including snoring and <font color="blue">obstructive sleep apnea</font></td>
    </tr>
    <tr>
      <td>In     addition, Gyrus has <font color="blue">recently introduced</font> a <font color="blue">bipolar system</font> for <font color="blue">tonsillectomy</font>     procedures that <font color="blue">competes directly with</font> our Coblation-based <font color="blue">tonsillectomy</font>     products</td>
    </tr>
    <tr>
      <td><font color="blue">Medtronic and Gyrus </font><font color="blue">both market sinus surgery packing products</font>     that <font color="blue">compete with</font> our newly acquired ATI products</td>
    </tr>
    <tr>
      <td>Many of our <font color="blue">competitors</font> have <font color="blue">significant</font>ly greater financial, <font color="blue">manufacturing</font>,     marketing, <font color="blue">distribution</font> and technical resources than we do</td>
    </tr>
    <tr>
      <td>Some of these     companies offer broad <font color="blue">product line</font>s that they may offer as a single package     and <font color="blue">frequently</font> offer <font color="blue">significant</font> <font color="blue">discounts</font> as a <font color="blue">competitive</font> tactic</td>
    </tr>
    <tr>
      <td>For     example, in order to compete <font color="blue">successfully</font>, we anticipate that we may have to     continue  to  offer  substantial  <font color="blue">discounts</font>  on our <font color="blue">controllers</font>, place     <font color="blue">controllers</font>  at  <font color="blue">customers sites at no cost</font> or in return for a minimum     <font color="blue">purchase commitment</font> of our <font color="blue">surgical wands</font> in order to <font color="blue">increase demand</font> for     our <font color="blue">disposable devices</font>, and that this <font color="blue"><font color="blue">competition</font> could</font> have a material     adverse effect on our business, <font color="blue">financial condition</font>, results of <font color="blue">operations</font>     and <font color="blue">future growth prospects</font></td>
    </tr>
    <tr>
      <td>Furthermore, some of our <font color="blue">competitors</font> utilize     <font color="blue">purchasing contracts</font> that link <font color="blue">discounts</font> on the purchase of one product to     purchases  of other products in their broad <font color="blue">product line</font>s</td>
    </tr>
    <tr>
      <td>Many of the     hospitals  in  the  United  States  have <font color="blue">purchasing contracts</font> with our     <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>Accordingly, <font color="blue">customers may</font> be <font color="blue">dissuaded from purchasing</font> our     products rather than the products of these <font color="blue">competitors</font> to the extent the     <font color="blue">purchase would</font> cause them to lose <font color="blue">discounts</font> on products</td>
    </tr>
    <tr>
      <td><font color="blue">We May Not Be Able to Keep Pace </font>with Technological Change or to Successfully     Develop New Products with Wide Market Acceptance, Which Could Cause Us to     Lose Business to Competitors        We may not be able to keep pace with <font color="blue">technology</font> or to develop <font color="blue">viable new</font>     products,  as we compete in a <font color="blue">market characterized by rapidly</font> changing     <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">future financial performance will depend</font> in part on our     ability to develop and <font color="blue"><font color="blue">manufacture</font> <font color="blue">new products</font></font> in a cost-<font color="blue">effective</font> manner,     to <font color="blue">introduce them</font> to the market on a <font color="blue">timely basis</font>, and to achieve market     <font color="blue">acceptance</font></td>
    </tr>
    <tr>
      <td>Factors which may result in delays of <font color="blue">new product <font color="blue">introduction</font>s</font>     or <font color="blue">cancellation</font> of our plans to <font color="blue">manufacture</font> and <font color="blue">market <font color="blue">new products</font></font> include     capital constraints, research and <font color="blue"><font color="blue">development</font> delays</font> or delays in acquiring     <font color="blue"><font color="blue">regulatory</font> approvals</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">new products</font> and <font color="blue">new product <font color="blue">introduction</font>s</font> may     fail to achieve expected levels of market <font color="blue">acceptance</font></td>
    </tr>
    <tr>
      <td>Factors impacting the     level of market <font color="blue">acceptance</font> include our ability to <font color="blue">successfully</font> implement new     <font color="blue">technologies</font>, the <font color="blue">timeliness</font> of our product <font color="blue">introduction</font>s, our product     pricing  strategies, and the financial and <font color="blue">technological resources</font> for     <font color="blue">product promotion</font> and <font color="blue"><font color="blue">development</font> available</font></td>
    </tr>
    <tr>
      <td><font color="blue">We Are Dependent </font>Upon Our <font color="blue">Arthroscopic System </font>       We <font color="blue">commercially introduced</font> our <font color="blue"><font color="blue">Arthroscopic System </font>in <font color="blue">December </font></font>1995</td>
    </tr>
    <tr>
      <td><font color="blue">Since     </font>our <font color="blue">Arthroscopic System </font>accounted for 60prca of our <font color="blue">product sales</font> in 2005, we     are <font color="blue">highly <font color="blue">dependent</font> on</font> its sales</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we will be able     to continue to <font color="blue">manufacture</font> <font color="blue">arthroscopy</font> products in <font color="blue">commercial quantities at</font>     acceptable  costs,  or that we will be able to continue to <font color="blue">market such</font>     products <font color="blue">successfully</font></td>
    </tr>
    <tr>
      <td>To achieve increasing disposable device <font color="blue">sales over</font> time, we believe we must     continue to penetrate the market in knee procedures, expand physicians’     <font color="blue">education with respect</font> to <font color="blue">Coblation </font><font color="blue">technology</font> and continue working on new     <font color="blue">product <font color="blue">development</font></font> efforts <font color="blue">specifically</font> for knee <font color="blue"><font color="blue">application</font>s</font></td>
    </tr>
    <tr>
      <td>Furthermore,     in  order  to maintain and increase current market <font color="blue">penetration</font> we must     continue to increase our installed base of <font color="blue">controllers</font> to generate increased     disposable device revenue</td>
    </tr>
    <tr>
      <td>To date, we have <font color="blue">placed at no charge</font> or have     priced our <font color="blue">arthroscopic</font> <font color="blue">controllers</font> at substantial <font color="blue">discounts</font> in order to     <font color="blue">stimulate demand</font> for our <font color="blue">disposable devices</font></td>
    </tr>
    <tr>
      <td>We believe that <font color="blue">surgeons will</font> not use our <font color="blue">products unless</font> they determine,     <font color="blue">based on</font> experience, <font color="blue">clinical data</font> and other factors, that these systems are     an <font color="blue">attractive <font color="blue">alternative</font></font> to <font color="blue">conventional</font> means of <font color="blue">tissue ablation</font></td>
    </tr>
    <tr>
      <td><font color="blue">There     </font>are  only  a  few <font color="blue">in<font color="blue">dependent</font></font>ly published clinical reports and limited     long-term  clinical follow-up to support the <font color="blue">marketing efforts</font> for our     Arthroscopic  System</td>
    </tr>
    <tr>
      <td>We believe that if <font color="blue">continued <font color="blue">recommendations</font></font> and     <font color="blue"><font color="blue">endorsement</font>s by influential surgeons</font> or long-term data do not support our     current claims of efficacy, our business, <font color="blue">financial condition</font>, results of     <font color="blue">operations</font>  and  <font color="blue"><font color="blue">future growth prospects</font> could</font> be <font color="blue"><font color="blue">materially</font> adversely</font>     affected</td>
    </tr>
    <tr>
      <td>21     ______________________________________________________________________    [63]Table of <font color="blue">Contents    </font>[64]Index to <font color="blue">Financial Statements       </font>Commercial Success of Products Outside of Our Core Businesses Is Uncertain        We have developed several <font color="blue"><font color="blue">application</font>s</font> for our <font color="blue">Coblation </font><font color="blue">technology</font> in     <font color="blue">spinal surgery</font>, <font color="blue">neurosurgery</font>, ENT surgery, cosmetic surgery, gynecology,     urology,  <font color="blue">cardiac surgery</font> and <font color="blue">general surgery</font></td>
    </tr>
    <tr>
      <td>At the present time, we     consider sports medicine, spine surgery <font color="blue">and ENT </font>surgery to be our core     <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>Sales  of  our  spinal  surgery  <font color="blue">and ENT </font><font color="blue">surgery products</font>     <font color="blue">collectively accounted</font> for 32prca and 34prca of our <font color="blue">product sales</font> in 2005 and     2004, respectively, such that <font color="blue">product sales</font> in our three core <font color="blue">businesses</font>     accounted for approximately 100prca of our <font color="blue">product sales</font> in 2005</td>
    </tr>
    <tr>
      <td>Our products     for <font color="blue">neurosurgery</font>, cosmetic surgery, gynecology, urology, <font color="blue">general surgery</font> and     cardiac  surgery,  our  non-core  business,  are  in <font color="blue">various stages</font> of     <font color="blue">commercialization</font> and <font color="blue">development</font>, and we may be required to undertake     time-consuming and costly <font color="blue">commercialization</font>, <font color="blue">development</font> and <font color="blue">additional</font>     <font color="blue"><font color="blue">regulatory</font> approval <font color="blue">activities</font></font> for any of these products</td>
    </tr>
    <tr>
      <td>If we do not     receive  future  <font color="blue">clearances</font> we may be unable to market these and other     products for specific <font color="blue">indications</font> and our business, <font color="blue">financial condition</font>,     results  of <font color="blue">operations</font> and <font color="blue"><font color="blue">future growth prospects</font> could</font> be <font color="blue">materially</font>     <font color="blue"><font color="blue">adversely affect</font>ed</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that <font color="blue">product <font color="blue">development</font></font> will ever     be <font color="blue">successfully</font> completed, that <font color="blue">regulatory</font> <font color="blue">clearances</font> or approvals, if     applied for, will be <font color="blue">granted by</font> the FDA or foreign <font color="blue">regulatory</font> <font color="blue">authorities</font> on     a <font color="blue">timely basis</font>, if at all, or that the <font color="blue">products will</font> ever achieve commercial     <font color="blue">acceptance</font></td>
    </tr>
    <tr>
      <td>We may have to make a <font color="blue">significant</font> investment in <font color="blue">additional</font> preclinical and     clinical testing, <font color="blue">regulatory</font>, physician training and sales and marketing     <font color="blue">activities</font>  to  further  develop  and  <font color="blue">commercialize</font> our <font color="blue">neurosurgery</font>,     gynecology, urology, cosmetic surgery, <font color="blue">general surgery</font> and <font color="blue">cardiovascular</font>     <font color="blue">product offerings</font></td>
    </tr>
    <tr>
      <td>Although we believe that these <font color="blue">products offer certain</font>     <font color="blue">advantages</font>, we <font color="blue">cannot assure</font> you that these <font color="blue">advantages</font> will be realized, or     if realized, that these <font color="blue">products will</font> result in any <font color="blue">meaningful benefits</font> to     physicians or patients</td>
    </tr>
    <tr>
      <td><font color="blue">Development  </font>and  <font color="blue">commercialization</font> of our current and future non-core     business  products are subject to the risks of <font color="blue">failure inherent</font> in the     <font color="blue">development</font> for <font color="blue">new <font color="blue">medical devices</font></font></td>
    </tr>
    <tr>
      <td>These risks include the following:           •   Such <font color="blue">products may</font> not be easy to use, may require extensive training     or may not be cost-<font color="blue">effective</font>;           •   New <font color="blue">products may</font> experience delays in testing or marketing;           •   There may be <font color="blue">unplanned <font color="blue">expenditures</font></font> or in <font color="blue">expenditures</font> above those     anticipated by us;           •   Such <font color="blue">products may</font> not be proven safe or <font color="blue">effective</font>;           •   Third <font color="blue">parties may</font> develop and market superior or <font color="blue">equivalent products</font>;           •   Such <font color="blue">products may</font> not receive <font color="blue">necessary</font> <font color="blue">regulatory</font> <font color="blue">clearances</font> or     approvals; and           •   <font color="blue">Proprietary </font>rights of third <font color="blue">parties may</font> preclude us and our     <font color="blue">collaborative partners from marketing <font color="blue">such products</font></font></td>
    </tr>
    <tr>
      <td>In addition, the success of our non-core business <font color="blue">products will</font> depend on     their <font color="blue">adoption as <font color="blue">alternative</font>s</font> to <font color="blue">conventional</font> means of <font color="blue">tissue ablation</font></td>
    </tr>
    <tr>
      <td>Clinical experience and follow-up data for our non-core business <font color="blue">indications</font>     are limited, and we have sold only a small number of units to date</td>
    </tr>
    <tr>
      <td>We     believe that <font color="blue">recommendations</font> and <font color="blue">endorsement</font> of <font color="blue">influential physicians</font> are     essential for market <font color="blue">acceptance</font> of <font color="blue">such products</font></td>
    </tr>
    <tr>
      <td>For information regarding the status of our <font color="blue"><font color="blue">regulatory</font> approvals</font> for our     products, see the information under the heading “<font color="blue">Government Regulation</font>”</td>
    </tr>
    <tr>
      <td><font color="blue">If Our <font color="blue">Costa Rica </font>Facility </font>is Unable to     Produce Our <font color="blue">Coblation </font>Products in Sufficient Quantities or With Adequate     Quality, or if <font color="blue">Our Operations </font>at <font color="blue">Our <font color="blue">Costa Rican </font>Facility </font>are Disrupted, We     Will Be Forced to Find Alternative <font color="blue">Manufacturing </font>Options, Which Could Cause     Sales to be Delayed or Increase Our <font color="blue">Manufacturing </font>Costs, Which Could Harm     Our Reputation and Profitability        Our  high-volume  disposable  devices  and  <font color="blue">controllers</font>  are primarily     <font color="blue">manufacture</font>d at our Company-owned <font color="blue">facility</font> in an <font color="blue">industrial park</font> in San     Jose, Costa Rica</td>
    </tr>
    <tr>
      <td>This <font color="blue">facility</font> commenced <font color="blue">operations</font> in 2002 and by year-end     2005 was producing approximately 99prca of our disposable device <font color="blue">requirements</font>,     including as of                                           22     ______________________________________________________________________    [65]Table of <font color="blue">Contents    </font>[66]Index to <font color="blue">Financial Statements       </font><font color="blue">December </font>31, 2005, 100prca of our <font color="blue">requirements</font> for <font color="blue">controllers</font></td>
    </tr>
    <tr>
      <td>If our Costa     Rica  <font color="blue">facility</font>  is  not  able  to produce <font color="blue">sufficient quantities</font> of our     <font color="blue">controllers</font> and other high-volume <font color="blue">Coblation </font><font color="blue">products with adequate quality</font>,     or if our <font color="blue">Costa Rica </font><font color="blue">operations</font> are disrupted for any reason, then we may be     forced to locate <font color="blue">alternative</font> <font color="blue">manufacturing</font> <font color="blue">facilities</font>, including <font color="blue">facilities</font>     operated <font color="blue">by <font color="blue">third parties</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Disruptions </font>may include, but are not limited to,     changes in the legal and <font color="blue">regulatory</font> environment in Costa Rica; slowdowns or     work <font color="blue">stoppages within</font> the <font color="blue">Costa Rican </font>customs <font color="blue">authorities</font>; acts of God and     other issues associated with <font color="blue">significant</font> <font color="blue">operations</font> that are remote from our     <font color="blue">headquarters</font> and <font color="blue">operations</font> centers</td>
    </tr>
    <tr>
      <td>Locating <font color="blue">alternative</font> <font color="blue">facilities</font> would     be time-consuming, would disrupt our production and cause <font color="blue">shipment delays</font>     and could result in damage to our reputation and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We cannot     guarantee that <font color="blue">alternative</font> <font color="blue">manufacturing</font> <font color="blue">facilities</font> offering the cost and     tax <font color="blue">advantages</font> associated with our <font color="blue">Costa Rica </font><font color="blue">facility</font> would be <font color="blue">available on</font>     favorable terms, or at all</td>
    </tr>
    <tr>
      <td>Our Business May Become Increasingly Susceptible to Risks Associated with     <font color="blue">International </font>Operations        <font color="blue">International </font> <font color="blue">operations</font>  are <font color="blue">generally</font> subject to a number of risks,     including:           •   <font color="blue">protectionist laws</font> and business practices that <font color="blue">favor local</font>     <font color="blue">competition</font>;           •   changes in <font color="blue">jurisdictional tax laws</font> including <font color="blue">laws regulating</font>     <font color="blue">intercompany transactions</font>;           •   <font color="blue">dependence on local vendors</font>;           •   multiple, conflicting and changing <font color="blue">governmental laws</font> and <font color="blue">regulations</font>;           •   <font color="blue"><font color="blue">difficult</font>ies</font> in <font color="blue">collecting accounts receivable</font>;           •   <font color="blue">seasonality</font> of <font color="blue">operations</font>;           •   <font color="blue"><font color="blue">difficult</font>ies</font> in staffing and managing foreign <font color="blue">operations</font>;           •   licenses, tariffs, and other <font color="blue">trade barriers</font>;           •   loss of <font color="blue">proprietary</font> information due to piracy, misappropriation or     <font color="blue">weaker laws</font> regarding <font color="blue">intellectual property protection</font>;           •   <font color="blue">foreign currency exchange rate <font color="blue">fluctuations</font></font>;           •   political and <font color="blue">economic instability</font>; and           •   <font color="blue"><font color="blue">acquisition</font>s</font> and related IPR&amp;D       We derived 21prca and 25prca of our <font color="blue">total revenue</font> for the years ended <font color="blue">December </font>31,     2005 and 2004, respectively, from customers located outside of the Americas</td>
    </tr>
    <tr>
      <td>We  expect <font color="blue">international</font> revenue to remain a large percentage of total     revenue and we believe that we <font color="blue">must continue</font> to expand our <font color="blue">international</font>     sales  <font color="blue">activities</font>  to  be  successful</td>
    </tr>
    <tr>
      <td>Historically, a majority of our     <font color="blue">international</font>  revenues  and  costs  have  been <font color="blue">denominated</font> in foreign     currencies, and we expect future <font color="blue">international</font> revenues and costs will be     <font color="blue">denominated</font> in foreign currencies</td>
    </tr>
    <tr>
      <td>Our <font color="blue">international</font> sales growth will be     limited if we are unable to establish appropriate foreign <font color="blue">operations</font>, expand     <font color="blue">international</font> sales channel management and support organizations, hire     <font color="blue">additional</font>  personnel,  develop <font color="blue">relationships with</font> <font color="blue">international</font> sales     <font color="blue">representatives</font>, and establish <font color="blue">relationships with</font> <font color="blue">additional</font> distributors</td>
    </tr>
    <tr>
      <td>In that case, our business, operating results and <font color="blue">financial condition</font> could     be <font color="blue">materially</font> <font color="blue"><font color="blue">adversely affect</font>ed</font></td>
    </tr>
    <tr>
      <td>Even if we are able to <font color="blue">successfully</font> expand     <font color="blue">international</font> <font color="blue">operations</font>, we cannot be certain that we will be able to     maintain or increase <font color="blue">international</font> market demand for our products</td>
    </tr>
    <tr>
      <td>Our Operating Results May Fluctuate        We achieved <font color="blue">profitability</font> in 1999 and, as of <font color="blue">December </font>31, 2005, we had     retained earnings of dlra5dtta6 million</td>
    </tr>
    <tr>
      <td>Results of <font color="blue">operations</font> may fluctuate     <font color="blue">significant</font>ly from quarter to quarter due to many factors, including the     following:           •   The <font color="blue">introduction</font> of new <font color="blue">product line</font>s;           •   <font color="blue">Increased </font><font color="blue">penetration</font> in existing <font color="blue"><font color="blue">application</font>s</font>;                                           23     ______________________________________________________________________    [67]Table of <font color="blue">Contents    </font>[68]Index to <font color="blue">Financial Statements       </font>  •   Product returns;           •   <font color="blue">Achievement </font>of research and <font color="blue">development</font> <font color="blue">milestones</font>;           •   The amount and timing of receipt and <font color="blue">recognition</font> of <font color="blue">license fees</font>;           •   <font color="blue">Manufacturing </font>or supply <font color="blue"><font color="blue">disruption</font>s</font>;           •   Internal systems <font color="blue">availability</font> and uptimes;           •   Timing of <font color="blue">expenditures</font>;           •   Absence of a backlog of orders;           •   Receipt of <font color="blue">necessary</font> <font color="blue"><font color="blue">regulatory</font> approvals</font>;           •   The level of market <font color="blue">acceptance</font> for our products;           •   <font color="blue">Acquisition </font>related in-process research and <font color="blue">development</font> write-offs;           •   Timing of the receipt of orders and <font color="blue">product shipments</font>; and           •   <font color="blue">Promotional </font>programs for our products</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot provide assurance</font> that <font color="blue">future quarterly <font color="blue">fluctuations</font> will</font> not     <font color="blue">adversely affect</font> our business, <font color="blue">financial condition</font>, results of <font color="blue">operations</font> of     <font color="blue">future growth prospects</font></td>
    </tr>
    <tr>
      <td>Our revenues and <font color="blue">profitability</font> will be <font color="blue">critically</font>     <font color="blue"><font color="blue">dependent</font> on whether</font> or not we can <font color="blue">successfully</font> continue to market our     Coblation-based <font color="blue">technology</font> <font color="blue">product line</font>s and continue to integrate our     recent <font color="blue"><font color="blue">acquisition</font>s</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> investors that we will maintain or     increase our revenues or level of <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>The Market Price of Our Stock May Be Highly Volatile        During the fiscal year ended <font color="blue">December </font>31, 2005 our <font color="blue">common stock</font> has traded     in a price range of dlra25dtta62 to dlra42dtta18 per share</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our     <font color="blue">common stock</font> could continue to fluctuate <font color="blue">substantially</font> due to a variety of     factors, including:           •   <font color="blue">Quarterly </font><font color="blue">fluctuations</font> in results of our <font color="blue">operations</font>;           •   Our ability to <font color="blue">successfully</font> <font color="blue">commercialize</font> our products;           •   <font color="blue">Announcements </font>regarding results of <font color="blue">regulatory</font> approval filing,     <font color="blue">clinical studies</font> or other testing, technological innovations or <font color="blue">new products</font>     <font color="blue">commercialize</font>d by us or our <font color="blue">competitors</font>;           •   <font color="blue">Developments </font>concerning government <font color="blue">regulations</font>, <font color="blue">proprietary</font> rights or     public concern as to the safety of our <font color="blue">technology</font>;           •   The execution of <font color="blue">new collaborative <font color="blue">agreements</font></font> and material changes in     our <font color="blue">relationships with</font> our business partners;           •   Market reaction to <font color="blue"><font color="blue">acquisition</font>s</font> and trends in sales, marketing, and     research and <font color="blue">development</font>;           •   Changes in coverage or earnings estimates by analysts;           •   Sales of <font color="blue">common stock</font> by existing <font color="blue">stockholders</font>; and           •   Economic and political <font color="blue">conditions</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> for our <font color="blue">common stock</font> may also be <font color="blue">affected by</font> our ability to     meet analysts’ expectations</td>
    </tr>
    <tr>
      <td>Any failure to meet such expectations, even     slightly,  could have an adverse effect on the <font color="blue">market price</font> and volume     <font color="blue">fluctuations</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">volatility</font> has had a <font color="blue">significant</font> effect on the market     prices of <font color="blue">securities issued by</font> many companies for <font color="blue">reasons unrelated</font> to the     operating performance of these companies</td>
    </tr>
    <tr>
      <td>In the past, following periods of     <font color="blue">volatility</font>  in the <font color="blue">market price</font> of a company’s securities, the risk of     securities class <font color="blue">action <font color="blue">litigation</font></font> has increased</td>
    </tr>
    <tr>
      <td>If similar <font color="blue">litigation</font> were     instituted against us, it could result in substantial costs and a diversion     of our management’s attention                                           24     ______________________________________________________________________    [69]Table of <font color="blue">Contents    </font>[70]Index to <font color="blue">Financial Statements       </font>and resources, which could have an adverse effect on our business, results     of <font color="blue">operations</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>See “Item 5: Market for Registrant’s     Common Equity, Related Stockholder Matters and Issuer Purchases of Equity     Securities,” for more information regarding <font color="blue">fluctuations</font> in the price of our     <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We May Be Unable to Effectively Protect Our Intellectual Property        Our  ability  to compete <font color="blue">effective</font>ly depends in part on developing and     maintaining the <font color="blue">proprietary</font> aspects of our <font color="blue">Coblation </font><font color="blue">technology</font> and our     acquired <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>We believe that our <font color="blue">issued patents</font> are <font color="blue">directed at</font>     the core <font color="blue">technology</font> used in our soft-tissue surgery systems, including both     multi-electrode  and <font color="blue">single electrode configurations</font> of our disposable     devices, as well as the use of <font color="blue">Coblation </font><font color="blue">technology</font> in <font color="blue">specific surgical</font>     procedures</td>
    </tr>
    <tr>
      <td>In addition, we believe that our <font color="blue">issued patents</font> are <font color="blue">directed at</font>     many of the core features of our acquired <font color="blue">technologies</font> from Opus, Parallax,     <font color="blue">Atlantech </font>and ATI       There is no assurance that the patents we have obtained, or any patents we     may  obtain  as  a  result of our pending US or <font color="blue">international</font> patent     <font color="blue"><font color="blue">application</font>s</font>, will provide any <font color="blue">competitive</font> <font color="blue">advantages</font> for our products</td>
    </tr>
    <tr>
      <td>We     also <font color="blue">cannot assure</font> investors that those <font color="blue">patents will</font> not be <font color="blue">successfully</font>     challenged, invalidated or <font color="blue">circumvented</font> in the future</td>
    </tr>
    <tr>
      <td>In addition, we     <font color="blue">cannot provide assurance</font> that <font color="blue">competitors</font>, many of which have substantial     resources and have made substantial investments in competing <font color="blue">technologies</font>,     have not <font color="blue">already applied</font> for or obtained, or will not seek to apply for and     obtain, patents that will prevent, limit or <font color="blue">interfere with</font> our ability to     make,  use  and  sell  our  <font color="blue">products either</font> in the <font color="blue"><font color="blue">United States</font> </font>or in     <font color="blue">international</font> markets</td>
    </tr>
    <tr>
      <td>Patent <font color="blue"><font color="blue">application</font>s</font> are maintained in secrecy for a     period after filing</td>
    </tr>
    <tr>
      <td>We may not be aware of all of the patents and patent     <font color="blue"><font color="blue">application</font>s</font> potentially adverse to our interests</td>
    </tr>
    <tr>
      <td>A number of medical device and other companies, universities and research     <font color="blue">institutions</font> have filed patent <font color="blue"><font color="blue">application</font>s</font> or have <font color="blue">issued patents</font> relating     to monopolar and/or bipolar electrosurgical methods and apparatus</td>
    </tr>
    <tr>
      <td>We have     received, and we may receive in the future, notifications of potential     conflicts of <font color="blue">existing patents</font>, pending patent <font color="blue"><font color="blue">application</font>s</font> and <font color="blue">challenges</font> to     the validity of <font color="blue">existing patents</font></td>
    </tr>
    <tr>
      <td>In addition, we have <font color="blue">become aware</font> of,     <font color="blue">potential conflicts</font> of <font color="blue">existing patents</font>, pending patent <font color="blue"><font color="blue">application</font>s</font> and     <font color="blue">challenges</font> to the validity of <font color="blue">existing patents</font></td>
    </tr>
    <tr>
      <td>In addition, we have become     aware of, and may <font color="blue">become aware</font> of in the future, patent <font color="blue"><font color="blue">application</font>s</font> and     <font color="blue">issued patents</font> that relate to our products and/or the surgical <font color="blue"><font color="blue">application</font>s</font>     and  issued  patents and, in some cases, have obtained internal and/or     <font color="blue">external opinions</font> of counsel regarding the relevance of <font color="blue">certain issued</font>     patents to our products</td>
    </tr>
    <tr>
      <td>We do not believe that our <font color="blue">products currently</font>     infringe any valid and enforceable claims of the <font color="blue">issued patents</font> that we have     reviewed</td>
    </tr>
    <tr>
      <td>However, if third-party patents or patent <font color="blue"><font color="blue">application</font>s</font> contain     claims <font color="blue">infringed by</font> our <font color="blue">technology</font> and such claims are ultimately determined     to be valid, we may not be able to obtain licenses to those <font color="blue">patents at</font> a     <font color="blue">reasonable cost</font>, if at all, or be able to develop or obtain <font color="blue">alternative</font>     <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to do <font color="blue">either would</font> have a material adverse effect     on our business, <font color="blue">financial condition</font>, results of <font color="blue">operations</font> and prospects</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> investors that we will not have to <font color="blue">defend ourselves</font> in     <font color="blue">court against allegations</font> of <font color="blue">infringement</font> of third-party patents, or that     <font color="blue">such defense would</font> be successful</td>
    </tr>
    <tr>
      <td>In addition to patents, we <font color="blue">rely on trade secrets</font> and <font color="blue">proprietary</font> know-how,     which we seek to protect, in part, <font color="blue">through <font color="blue">confidential</font>ity</font> and <font color="blue">proprietary</font>     information <font color="blue">agreements</font></td>
    </tr>
    <tr>
      <td>We require our <font color="blue">key employees</font> and <font color="blue">consultants</font> to     execute <font color="blue">confidential</font>ity <font color="blue">agreements</font> upon the <font color="blue">commencement</font> of an <font color="blue">employment</font> or     <font color="blue">consulting relationship with us</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">agreements</font> <font color="blue">generally</font> provide that all     <font color="blue">confidential</font> information, developed or made known to the individual during     the  course  of  the  individual’s relationship with us, is to be kept     <font color="blue">confidential</font> and not disclosed to <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">agreements</font> also     <font color="blue">generally</font> provide that <font color="blue">inventions</font> conceived by the individual in the course     of rendering services to us shall be our <font color="blue">exclusive property</font></td>
    </tr>
    <tr>
      <td>We cannot     <font color="blue">assure investors</font> that <font color="blue">employees will</font> not breach such <font color="blue">agreements</font>, that we     would have <font color="blue">adequate remedies</font> for any breach or that our <font color="blue">trade secrets will</font>     not <font color="blue">otherwise become known</font> to or be <font color="blue">in<font color="blue">dependent</font></font>ly developed by <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>We May Become Subject to Patent Litigation        The medical device industry has <font color="blue">been characterized by</font> extensive <font color="blue">litigation</font>     regarding patents and other <font color="blue">intellectual property rights</font>, and companies in     the medical device industry have <font color="blue">employed intellectual property</font>                                           25     ______________________________________________________________________    [71]Table of <font color="blue">Contents    </font>[72]Index to <font color="blue">Financial Statements       </font><font color="blue">litigation</font> to gain a <font color="blue">competitive</font> advantage</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> investors that     we will not become subject to patent <font color="blue">infringement</font> claims or <font color="blue">litigation</font> or     <font color="blue">interference proceedings</font> declared by the USPTO, to determine the priority of     <font color="blue">inventions</font></td>
    </tr>
    <tr>
      <td><font color="blue">In February </font>1998, we filed a <font color="blue">lawsuit against</font> Ethicon, Inc,     Mitek Surgical Products, a division of Ethicon, Inc, and GyneCare, Inc</td>
    </tr>
    <tr>
      <td>alleging, among other things, <font color="blue">infringement</font> of several of our patents</td>
    </tr>
    <tr>
      <td>The     parties  <font color="blue">subsequently</font>  settled  this  lawsuit</td>
    </tr>
    <tr>
      <td>Under the terms of the     settlement, Ethicon, Inc</td>
    </tr>
    <tr>
      <td>has licensed a portion of our US patents for     <font color="blue">current products</font> in the <font color="blue">arthroscopy</font> and hysterocopic gynecology markets</td>
    </tr>
    <tr>
      <td>The     <font color="blue">settlement agreement also established</font> a procedure for resolution of certain     potential  <font color="blue">intellectual property disputes</font> in these <font color="blue">two markets without</font>     <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>Under this procedure, the <font color="blue">licenses granted</font> in the <font color="blue">Ethicon     </font>settlement have <font color="blue">been extended</font> to Australia, Canada and Japan</td>
    </tr>
    <tr>
      <td>In June 2000,     we filed a <font color="blue">lawsuit against</font> Stryker, alleging <font color="blue">infringement</font> of several of our     patents</td>
    </tr>
    <tr>
      <td>The lawsuit has <font color="blue">been settled</font> and under the terms of the settlement,     Stryker has licensed a portion of our <font color="blue">worldwide patents</font> for products in the     <font color="blue">arthroscopy</font> market</td>
    </tr>
    <tr>
      <td>On July 25, 2001, we filed a <font color="blue">lawsuit against</font> Smith &amp; Nephew, Inc</td>
    </tr>
    <tr>
      <td>The     lawsuit alleged, among other things, that Smith &amp; Nephew was infringing     <font color="blue">three patents issued</font> to ArthroCare</td>
    </tr>
    <tr>
      <td>Specifically, Smith &amp; Nephew uses,     imports, markets and sells electrosurgical products under the names of     Dyonics Control RF System, ElectroBlade and Saphyre^™ that infringed these     patents</td>
    </tr>
    <tr>
      <td>On April 3, 2003, Smith &amp; Nephew filed a <font color="blue">lawsuit against</font> us in the United     States District Court, Western Tennessee alleging that we <font color="blue">infringed two</font>     Smith &amp; Nephew patents—nos</td>
    </tr>
    <tr>
      <td>In addition, Smith &amp;     Nephew alleged that we were in violation of Section 43(A) of the <font color="blue">Lanham Act     </font>for <font color="blue">allegedly</font> making false or misleading statements to deceive potential     purchasers of Smith &amp; Nephew’s <font color="blue">medical devices</font></td>
    </tr>
    <tr>
      <td>Smith &amp; Nephew requested the     Court to issue <font color="blue">preliminary</font> and permanent injunction preventing <font color="blue"><font color="blue">ArthroCare </font>    </font>from further <font color="blue">infringement</font> of the above-mentioned patents and from making     <font color="blue">further false</font> or <font color="blue">misleading statements concerning</font> Smith &amp; Nephew’s medical     devices</td>
    </tr>
    <tr>
      <td>These lawsuits were dismissed and the claims <font color="blue">settled pursuant</font> to a     <font color="blue">Settlement and License Agreement </font>between <font color="blue">ArthroCare </font>and Smith &amp; Nephew on     <font color="blue">September </font>2,  2005</td>
    </tr>
    <tr>
      <td>As a consequence of this settlement, we received a     one-time cash payment at signing, which has been recorded as a reduction of     legal fees in general and <font color="blue">administrative</font> expenses, and will receive a series     of related milestone payments over the next twelve months, which will also     be record in general and <font color="blue">administrative</font> expenses</td>
    </tr>
    <tr>
      <td>This <font color="blue">agreement settles</font> all     <font color="blue">legal disputes between</font> <font color="blue">ArthroCare </font>and Smith &amp; Nephew, including the pending     <font color="blue">legal matters</font> in <font color="blue"><font color="blue">Delaware </font>and Tennessee </font>described above</td>
    </tr>
    <tr>
      <td>On <font color="blue">December </font>15, 2005, Bonutti IP, LLC filed a <font color="blue">lawsuit against</font> us in the     <font color="blue"><font color="blue">United States</font> </font>District Court, Southern District of Illinois alleging that     our <font color="blue">Opus AutoCuff </font><font color="blue">anchoring system infringed ten</font> Bonutti patents (Nos</td>
    </tr>
    <tr>
      <td>Bonutti requested the Court to award     damages and to issue a <font color="blue">permanent injunction preventing us from further</font>     <font color="blue">infringement</font> of the above-mentioned patents</td>
    </tr>
    <tr>
      <td>Upon <font color="blue">initial review</font>, we believe     that  these  claims  have  no  merit and we intend to <font color="blue">defend ourselves</font>     <font color="blue">vigorously</font></td>
    </tr>
    <tr>
      <td>We Must Obtain Governmental Clearances or Approvals Before We Can Sell Our     Products; We Must Continue to Comply with Applicable Laws and Regulations        Our products are considered <font color="blue">medical devices</font> and are subject to extensive     regulation in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>We must obtain <font color="blue">premarket clearance</font> or     <font color="blue">approval by</font> the FDA for each of our products and <font color="blue">indications</font> before they can     be <font color="blue">commercialize</font>d</td>
    </tr>
    <tr>
      <td><font color="blue">International </font>sales of our products are also subject to     strict <font color="blue">regulatory</font> <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>For more information about the US and     foreign  <font color="blue">regulatory</font>  <font color="blue">requirements</font>,  see  information under the heading     “<font color="blue">Government Regulation</font>” above</td>
    </tr>
    <tr>
      <td><font color="blue">Information </font>pertaining to our products and <font color="blue">indications</font> before they can be     <font color="blue">commercialize</font>d can be <font color="blue">found under</font> the heading “<font color="blue">Government Regulation</font>s” in     Item 1, above</td>
    </tr>
    <tr>
      <td>26     ______________________________________________________________________    [73]Table of <font color="blue">Contents    </font>[74]Index to <font color="blue">Financial Statements       </font>We Face Uncertainty Over <font color="blue">Reimbursement </font>       Failure by physicians, hospitals and other users of our products to obtain     <font color="blue">sufficient <font color="blue">reimbursement</font> from <font color="blue">health care payers</font></font> for procedures in which our     products  are  used,  or  adverse changes in <font color="blue">environmental</font> and private     third-party payers’ policies toward <font color="blue">reimbursement</font> for <font color="blue">such procedures would</font>     have a material adverse effect on our business, <font color="blue">financial condition</font>, results     of <font color="blue">operations</font> and <font color="blue">future growth prospects</font></td>
    </tr>
    <tr>
      <td><font color="blue">Reimbursement </font>for <font color="blue">arthroscopic</font>,     <font color="blue">spinal surgery</font>, <font color="blue">neurosurgery</font>, ENT surgery, gynecology, urology, cardiology     and  general  <font color="blue">surgery procedures</font> performed using our devices that have     received FDA clearance has <font color="blue">generally</font> been available in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Typically, cosmetic <font color="blue">surgery procedures</font> are not reimbursed</td>
    </tr>
    <tr>
      <td>We are unable to predict what changes will be made in the <font color="blue">reimbursement</font>     methods used by third-party health care payors</td>
    </tr>
    <tr>
      <td>In addition, some health     <font color="blue">care providers</font> are moving toward a <font color="blue">managed care system</font> in <font color="blue">which providers</font>     contract to <font color="blue">provide comprehensive health care</font> for a fixed cost per person</td>
    </tr>
    <tr>
      <td>Managed <font color="blue">care providers</font> are attempting to control the cost of <font color="blue">health care by</font>     <font color="blue">authorizing fewer elective surgical procedures</font></td>
    </tr>
    <tr>
      <td>We anticipate that in a     prospective payment system, such as the <font color="blue">diagnosis</font> related group system     <font color="blue">utilized by</font> Medicare, and in many <font color="blue">managed care system</font>s used by private     <font color="blue">health care payers</font>, the cost of our <font color="blue">products will</font> be <font color="blue">incorporated into</font> the     <font color="blue">overall cost</font> of the procedure and that <font color="blue">there will</font> be no separate, <font color="blue">additional</font>     <font color="blue">reimbursement</font> for our products</td>
    </tr>
    <tr>
      <td>If  we obtain the <font color="blue">necessary</font> <font color="blue">international</font> <font color="blue"><font color="blue">regulatory</font> approvals</font>, market     <font color="blue">acceptance</font> of our products in <font color="blue">international</font> markets would be <font color="blue">dependent</font>, in     part, upon the <font color="blue">availability</font> of <font color="blue">reimbursement</font> within prevailing health care     payment  systems</td>
    </tr>
    <tr>
      <td><font color="blue">Reimbursement </font> and  health  care payment systems in     <font color="blue">international</font>  markets  vary <font color="blue">significant</font>ly by country and include both     government-sponsored health care and private insurance</td>
    </tr>
    <tr>
      <td>We intend to seek     <font color="blue">international</font> <font color="blue">reimbursement</font> approvals, although we <font color="blue">cannot assure</font> investors     that any <font color="blue">such approvals will</font> be obtained in a <font color="blue">timely manner</font>, if at all</td>
    </tr>
    <tr>
      <td><font color="blue">Nucleoplasty </font>is our version of <font color="blue"><font color="blue">percutaneous</font> <font color="blue">discectomy</font></font>, where tissue is     <font color="blue">removed from</font> the nucleus to <font color="blue">decompress</font> the disc</td>
    </tr>
    <tr>
      <td>Several payors consider     <font color="blue">percutaneous</font>  <font color="blue">discectomy</font> in any form <font color="blue">investigational</font>, and <font color="blue">others cover</font>     <font color="blue"><font color="blue">percutaneous</font> <font color="blue">discectomy</font></font>, but consider <font color="blue">Nucleoplasty </font><font color="blue">investigational</font></td>
    </tr>
    <tr>
      <td>There is     no assurance that we will be able to obtain <font color="blue">coverage with</font> these payors for     <font color="blue"><font color="blue">percutaneous</font> <font color="blue">discectomy</font></font> in general, and <font color="blue">Nucleoplasty </font><font color="blue">specifically</font></td>
    </tr>
    <tr>
      <td><font color="blue">We Are Dependent </font>on Key Suppliers        Some  of  the key <font color="blue">components</font> of our products are purchased from single     vendors</td>
    </tr>
    <tr>
      <td>If  the supply of materials from a sole source supplier were     <font color="blue">interrupted</font>,  <font color="blue">replacement</font>  or <font color="blue">alternative</font> sources might not be readily     obtainable  due  to  the  <font color="blue">regulatory</font>  <font color="blue">requirements</font>  applicable  to our     <font color="blue">manufacturing</font> <font color="blue">operations</font> or the <font color="blue">availability</font> of <font color="blue">certain product drawings</font>     and/or  <font color="blue">specifications</font></td>
    </tr>
    <tr>
      <td>In addition, a new or <font color="blue">supplemental filing with</font>     applicable  <font color="blue">regulatory</font>  <font color="blue">authorities</font> may require <font color="blue">clearance prior</font> to our     marketing a <font color="blue">product containing new</font> material</td>
    </tr>
    <tr>
      <td>This <font color="blue">clearance process may</font> take     a substantial period of time and we <font color="blue">cannot assure</font> investors that we would be     able to obtain the <font color="blue">necessary</font> <font color="blue">regulatory</font> approval for a new material to be     used in our <font color="blue">products on</font> a <font color="blue">timely basis</font>, if at all</td>
    </tr>
    <tr>
      <td>This could create supply     <font color="blue"><font color="blue">disruption</font>s</font> that would <font color="blue"><font color="blue">materially</font> adversely</font> affect our business, financial     condition, results of <font color="blue">operations</font> and <font color="blue">future growth prospects</font></td>
    </tr>
    <tr>
      <td>In  addition,  we  currently  single  source our <font color="blue">product sterilization</font>     <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>While there are <font color="blue">alternate sources available</font>, we would be     required to qualify and validate a new supplier(s), which could lead to a     <font color="blue">disruption</font> in our operation and ability to <font color="blue">supply products</font> for a period of     time</td>
    </tr>
    <tr>
      <td>We are also <font color="blue">dependent</font> on the performance of DHL, our <font color="blue">logistics partner</font></td>
    </tr>
    <tr>
      <td>Should this supplier experience a work stoppage for <font color="blue">whatever reason</font>, we     would be unable to <font color="blue">supply products</font> to its <font color="blue">customers on</font> a <font color="blue">timely basis</font></td>
    </tr>
    <tr>
      <td><font color="blue">This     </font>work <font color="blue">stoppage could</font> take the form of labor action, <font color="blue">significant</font> weather     events or extended systems downtime, which could <font color="blue"><font color="blue">materially</font> adversely</font> affect     our business</td>
    </tr>
    <tr>
      <td>27     ______________________________________________________________________    [75]Table of <font color="blue">Contents    </font>[76]Index to <font color="blue">Financial Statements       </font>We Have Limited Marketing and Sales Experience        We currently have limited experience in marketing and selling our products</td>
    </tr>
    <tr>
      <td>To the extent that we have established or will enter into <font color="blue">distribution</font>     <font color="blue">arrangements</font> for the sale of our products, we are and will be <font color="blue">dependent</font> upon     the efforts of <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>We are marketing and selling our <font color="blue">arthroscopic</font>     surgery, <font color="blue">spinal surgery</font> <font color="blue">and ENT </font>surgery <font color="blue">product line</font>s in the <font color="blue"><font color="blue">United States</font> </font>    through a <font color="blue">combination</font> of a <font color="blue">direct sales force</font> and a network of <font color="blue">in<font color="blue">dependent</font></font>     <font color="blue">distributors supported by regional sales managers</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">distributors sell</font>     <font color="blue">arthroscopy</font>, <font color="blue">spinal surgery</font> <font color="blue">and ENT </font><font color="blue">surgery products</font> for a number of other     <font color="blue">manufacture</font>rs</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot provide assurance</font> that these <font color="blue">distributors will</font>     commit the <font color="blue">necessary</font> resources to <font color="blue">effective</font>ly market and sell our sports     medicine, <font color="blue">spinal surgery</font> <font color="blue">and ENT </font>surgery <font color="blue">product line</font>s, or that they will be     successful in selling our products</td>
    </tr>
    <tr>
      <td><font color="blue">Delaware </font>Law, Provisions in Our Charter and Our Stockholder Rights Plan     Could Make the <font color="blue">Acquisition </font>of Our Company By Another Company More Difficult        Our <font color="blue">stockholder rights</font> plan and <font color="blue">certain provisions</font> of our <font color="blue">certificate</font> of     <font color="blue">incorporation</font> and <font color="blue">bylaws may</font> have the effect of making it more <font color="blue">difficult</font> for     a <font color="blue">third party</font> to acquire, or of <font color="blue">discouraging</font> a <font color="blue">third party</font> from attempting     to acquire, control of our company</td>
    </tr>
    <tr>
      <td>This <font color="blue">could limit</font> the price that certain     <font color="blue">investors might</font> be willing to pay in the future for shares of our common     stock</td>
    </tr>
    <tr>
      <td>Some provisions of our <font color="blue">certificate</font> of <font color="blue">incorporation</font> and <font color="blue">bylaws allow</font>     us  to <font color="blue">issue <font color="blue">preferred stock</font> without</font> any vote or <font color="blue">further action by</font> the     <font color="blue">stockholders</font>, to eliminate the right of <font color="blue">stockholders</font> to act by written     <font color="blue">consent without</font> a meeting, to <font color="blue">specify procedures</font> for <font color="blue"><font color="blue">director nominations</font> by</font>     <font color="blue">stockholders</font>  and  submission  of other proposals for <font color="blue">consideration at</font>     <font color="blue">stockholder meetings</font>, and to <font color="blue">eliminate cumulative voting</font> in the election of     <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>Some provisions of <font color="blue">Delaware </font><font color="blue">law applicable</font> to <font color="blue">us could also delay</font>     or make more <font color="blue">difficult</font> a merger, tender offer or <font color="blue"><font color="blue">proxy contest</font> involving us</font>,     including Section 203, which prohibits a <font color="blue">Delaware </font><font color="blue">corporation from</font> engaging     in any business <font color="blue">combination</font> with any <font color="blue">interested stockholder</font> for a period of     three years unless certain <font color="blue">conditions</font> are met</td>
    </tr>
    <tr>
      <td>Our <font color="blue">stockholder rights</font> plan,     the  <font color="blue">possible issuance</font> of <font color="blue">preferred stock</font>, the procedures required for     <font color="blue">director nominations</font> and <font color="blue">stockholder proposals</font> and <font color="blue">Delaware </font>law could have     the effect of delaying, deferring or preventing a change in control of     ArthroCare, including without limitation, <font color="blue">discouraging</font> a <font color="blue">proxy contest</font> or     making more <font color="blue">difficult</font> the <font color="blue">acquisition</font> of a substantial block of our common     stock</td>
    </tr>
    <tr>
      <td><font color="blue">Beginning  </font>with  Fiscal 2006, We are <font color="blue">Required to Recognize Expense </font>for     Stock-Based Compensation Related to Employee Stock Options and Employee     Stock Purchases, and the Recognition of This Expense Could Cause the Trading     Price of Our Common Stock to Decline        In <font color="blue">December </font>2004, the <font color="blue">Financial Accounting Standards Board </font>issued <font color="blue">Statement </font>    of Financial Accounting Standards Nodtta 123R (“<font color="blue">Statement </font>123R”), pursuant to     which we must measure all stock-based compensation awards, including grants     of <font color="blue">employee stock</font> options, using a <font color="blue"><font color="blue">fair value</font> method</font> and <font color="blue">record such expense</font>     in our <font color="blue">consolidated <font color="blue">financial statements</font></font></td>
    </tr>
    <tr>
      <td>Through 2005, we disclosed such     expenses  on  a  pro  forma basis in the notes to our <font color="blue">annual financial</font>     statements, but did not record a charge for <font color="blue"><font color="blue">employee stock</font> option expense</font> in     the reported <font color="blue">financial statements</font></td>
    </tr>
    <tr>
      <td><font color="blue">On January </font>1, 2006 we adopted <font color="blue">Statement </font>    123R, which requires the <font color="blue">measurement</font> and <font color="blue">recognition</font> of <font color="blue">compensation expense</font>     for all stock-based compensation <font color="blue">based on</font> estimated <font color="blue"><font color="blue">fair value</font>s</font></td>
    </tr>
    <tr>
      <td>This will     be reflected in our <font color="blue">first quarter</font> 2006 Form 10-Q and, as a result, our     operating results for the <font color="blue">first quarter</font> of fiscal 2006 and <font color="blue">beyond will</font>     contain a charge for stock-based compensation related to <font color="blue">employee stock</font>     options and <font color="blue">employee stock</font> purchases</td>
    </tr>
    <tr>
      <td>The <font color="blue">application</font> of <font color="blue">Statement </font>123R     requires the use of an option-pricing model to determine the <font color="blue">fair value</font> of     share-based payment awards</td>
    </tr>
    <tr>
      <td>This <font color="blue">fair value</font> determination is <font color="blue">affected by</font> our     <font color="blue">stock price as well as assumptions</font> regarding a number of <font color="blue">highly complex</font> and     <font color="blue">subjective variables</font></td>
    </tr>
    <tr>
      <td>These variables include, but are not limited to, our     expected stock price <font color="blue">volatility</font> over the term of the awards, and actual and     anticipated  employee  <font color="blue">stock option exercise behaviors</font></td>
    </tr>
  </tbody>
</table>